Conflict of Interest Declaration
The ILCOR Continuous Evidence Evaluation process is guided by a rigorous ILCOR Conflict of Interest policy. The following Task Force members and other authors were recused from the discussion as they declared a conflict of interest: None.
The following Task Force members and other authors declared an intellectual conflict of interest and this was acknowledged and managed by the Task Force Chairs and Conflict of Interest committee:
One author (MT) participated in the van Zanten 2021 RCT’s design and protocol development, but was not involved in the execution, data analysis, data interpretation or manuscript preparation. She was excluded from bias assessment of this study. One author (YR) holds patents for pulse oximeter technology to guide oxygen titration in the delivery room. Georg Schmölzer and Peter Davis are the authors of one study {Schmölzer 2012 37}. Both acknowledged their potential intellectual conflicts of interest and participated in the Task Force discussion of the consensus on science and treatment recommendations.
CoSTR Citation
Fuerch JH, Rabi Y, Thio M, Halamek LP, Costa-Nobre DT, de Almeida MF, Davis PG, El-Naggar W, Fabres JG, Fawke J, Nakwa FL, Foglia EE, Guinsburg R, Hosono S, Isayama T, Kapadia VS, Kawakami MD, Kim HS, Lee H, Madar RJ, McKinlay C, Perlman JM, Roehr CC, Rüdiger M, Schmölzer GM, Sugiura T, Trevisanuto D, Weiner GM, Wyllie JP, Liley HG, Wyckoff MH. Respiratory Function Monitoring (NLS#806 [Internet] Brussels, Belgium. International Liaison Committee on Resuscitation (ILCOR) Neonatal Life Support Task Force, Available from http://ilcor.org
Methodological Preamble (and Link to Published Systematic Review)
This PICOST was prioritized by the Neonatal Life Support Task Force because the question had not been updated since 2015. The literature search for the previous CoSTR {Perlman 2015 S204} had found only one eligible study that used a device to assess respiratory function based in a small (n=49) pilot RCT, resulting in low certainty evidence (downgraded for risk of bias and imprecision) {Schmölzer 2012 37}. No evidence was found regarding time to heart rate >100 bpm, neurologically intact survival, bronchopulmonary dysplasia or pneumothorax. Treatment recommendation suggested against the routine use of flow and volume monitoring for babies receiving positive pressure ventilation at birth, until more evidence became available.
The task force was aware that additional randomized trials examining the use of a respiratory function monitor device had been completed since the previous review. The above mentioned RCT has also been included in the current CoSTR {Schmölzer 2012 377; Zeballos Sarrato 2019 1368; van Zanten 2021 317}.
The continuous evidence process for the creation of Consensus of Science and Treatment Recommendations (CoSTR) started with a systematic review of respiratory function monitoring in the delivery room (Rabi, 2021 PROSPERO 2021 CRD42021278169) conducted by Janene H. Fuerch, Yacov Rabi, Marta Thio, and Louis P. Halamek. Evidence from neonatal literature was sought and considered by the Neonatal Life Support Task Force and clinical content experts. These data were considered when formulating the Treatment Recommendations.
Systematic Review
Not yet available.
PICOST
The PICOST (Population, Intervention, Comparator, Outcome, Study Designs, and Time Frame)
Population: In newborn infants receiving respiratory support at birth
Intervention: does the display of respiratory function monitoring (RFM)
Comparator: no display of RFM
Outcomes: Improve resuscitation [time to HR > 100bpm in delivery room (starting from birth), achieving desired tidal volumes (TV) in the delivery room (measure of respiratory function), percentage maximum mask leak in the delivery room (while using facemask ventilation), rate of intubation in the delivery room, air leaks (pneumothorax, pneumomediastinum, pneumopericardium, pulmonary interstitial emphysema) reported either individually or as a composite outcome within 24 hours of delivery], and/or improve clinical outcomes [death before discharge, severe Intraventricular hemorrhage (IVH) grades 3 or 4, bronchopulmonary dysplasia (BPD) / chronic lung disease (CLD) (any), duration of respiratory support, (i.e. nasal continuous airway pressure and ventilation via an endotracheal tube considered separately and in total (number of days))].
Outcomes ratings using the GRADE classifications of critical or important were based on a consensus for international neonatal resuscitation guidelines (range 1-3 low importance for decision-making, 4-6 important but not critical for decision-making, 7-9 critical for decision-making) {Strand 2020 328}. No subgroups were defined a priori. Outcomes were converted into main outcomes and additional outcomes for submission to PROSPERO. All included randomized controlled trials (RCTs) compared an RFM that was visible to the resuscitator versus one that was masked. If necessary, study authors were contacted to request missing data.
Study Designs: RCTs, quasi-RCTs, and non-randomized studies (non-randomized controlled trials, interrupted time series, controlled before-and-after studies, cohort studies) were eligible for inclusion. Unpublished studies (e.g., conference abstracts, trial protocols) were excluded. Outcomes from observational studies were assessed if there were fewer than 2 included RCTs/quasi-RCTs or if the certainty of evidence from RCTs/quasi-RCTs was scored very low.
Timeframe: All years and all languages were included as long as there was an English abstract. The literature search was updated to December 31, 2021.
PROSPERO registration:
The review was registered with PROSPERO CRD42021278169.
Risk of Bias:
Risk of bias (RoB) was assessed by outcome using the Cochrane ROB2 tool {Sterne 2019 366} for RCTs. RoB for each outcome was summarized across studies. Statistical heterogeneity was considered present if the I2 statistic was >50%. Imprecision was considered present if the confidence interval for the estimate of effect was wide and/or if the total number of participants included was less than optimal information size (OIS) for the outcome under consideration. OIS was calculated as the sample size required for a single, adequately powered RCT {Dupont 1974 274}.
Overall, study-level RoB was high. The ability to view the RFM was an intervention of interest and did not serve as a major plausible risk of performance bias from a lack of blinding the healthcare provider, as might otherwise be expected. However, some concerns regarding the blinding of participants and personnel. The risk of bias for outcome assessment was low because the analysis and interpretation of outcomes were conducted by researchers blinded to the group allocation. Zeballos Sarrato et.al. listed this primary outcome as tidal volume in the trial protocol (US ClinicalTrials.gov PRS, ID:NCT02748720) while they reported the primary outcome as need for surfactant, therefore the trial had some concerns for selective reporting {Zeballos Sarrato 2019 1368}. Schmölzer et.al. had unclear risk of selective reporting as there were some secondary outcomes in the trial registry that were not reported in the manuscript {Schmölzer 2012 377}.
All outcomes selected for GRADE assessment, were rated as very low or low certainty evidence. For most outcomes, this uncertainty was attributable to the risk of bias described above and imprecision.
Consensus on Science
COMPARISON: Display of respiratory function monitoring compared with no respiratory function monitoring display during neonatal resuscitation immediately after birth.
The systematic review identified 3 RCTs {Schmölzer 2012 377; Zeballos Sarrato 2019 1368; van Zanten 2021 317}, involving 443 newborns. One newborn infant died in the delivery room in the van Zanten et.al study which accounted for the total of 443 newborns, there is one less newborn reported in many of the longer-term outcomes due to this death.
In response to resuscitation:
For the important outcome intubation in the delivery room, evidence of very low certainty (downgraded for risk of bias, inconsistency and imprecision) from 3 randomized controlled trials (RCTs) {Schmölzer 2012 377; Zeballos Sarrato 2019 1368; van Zanten 2021 317} involving 443 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.90, 95% CI 0.55 – 1.48; p=0.69; I2 = 61%).
For the important outcome of achieving desired tidal volumes in the delivery room, evidence of low certainty (downgraded for risk of bias and imprecision) from 2 RCTs {Schmölzer 2012 377; van Zanten 2021 317} involving 337 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.96, 95% confidence interval (CI) 0.69 – 1.34; p=0.8; I2 = 0%).
For the important outcome of pneumothorax, evidence of low certainty (downgraded for risk of bias and imprecision) from 2 RCTs {Zeballos Sarrato 2019 1368; van Zanten 2021 317} involving 393 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.54, 95% CI 0.26 – 1.13; p=0.10; I2 = 0%).
For the important outcome of time to heart rate >100bpm in the delivery room, no data were reported in the included studies.
For the outcome of face-mask leak, the 3 RCTs could not be meta-analyzed as the measurement of leak was reported differently in each study. One trial reported median (IQR) percentage of leak per infant and found less leak when RFM was displayed (p=0.01) {Schmölzer 2012 377}. Another trial reported percentage of leak >75% over all inflations and found less leak when RFM was displayed (p=0.001) {Zeballos Sarrato 2019 1368}. The third and largest trial reported median (IQR) percentage of leak >60% per infant and found no significant difference in leak (p=0.126) between RFM displayed and the RFM not displayed {van Zanten 2021 317}.
Longer-term clinical outcomes:
For the critical outcome of death before hospital discharge, evidence of low certainty (downgraded for risk of bias and imprecision) from 3 RCTs {Schmölzer 2012 377; Zeballos Sarrato 2019 1368; van Zanten 2021 317} involving 442 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 1.00 95% CI 0.66 – 1.52; p=0.99; I2 = 0%).
For the critical outcome of severe intraventricular hemorrhage (grades 3 or 4), evidence of low certainty (downgraded for risk of bias and imprecision) from 1 RCT {van Zanten 2021 317} involving 287 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.96 95% CI 0.38 – 2.42; p=0.93). Statistical heterogeneity could not be calculated because events occurred in only one trial {van Zanten 2021 317}.
For the important outcome of intraventricular hemorrhage (all grades), evidence of low certainty (downgraded for risk of bias and imprecision) from 2 RCTs {Zeballos Sarrato 2019 1368; van Zanten 2021 317} involving 393 patients suggests possible clinical benefit from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.69 95% CI 0.49-0.96; p=0.03; I2 = 0%).
For the important outcome of bronchopulmonary dysplasia/chronic lung disease (any), evidence of low certainty (downgraded for risk of bias and imprecision) from 2 RCTs {Zeballos Sarrato 2019 1368, van Zanten 2021 317} involving 393 patients could not exclude clinical benefit or harm from displaying a respiratory function monitor compared to not displaying a respiratory function monitor (RR 0.85 95% CI 0.7 – 1.04; p=0.12; I2 = 0%).
Subgroup Analyses:
No subgroup analyses were pre-planned or performed.
Treatment Recommendations
There is insufficient evidence to make a recommendation for or against the use of a respiratory function monitor in newborn infants receiving respiratory support at birth (low certainty evidence).
Justification and Evidence to Decision Framework Highlights
In making this recommendation, the Neonatal Life Support Task Force acknowledges the following:
For newborn infants who receive respiratory support at birth, the Task Force did not make a recommendation for or against the use of a respiratory function monitor in part because of the low confidence in effect estimates for either benefit or harm (low certainty evidence).
One study reported the proportion of infants with tidal volume >8mL/kg {Zeballos Sarrato, 2019 1368} showing less excessive tidal volume when using RFM in infants <30 weeks' gestation (p<0.001 in n=21 infants 28-29 weeks' gestation, p<0.001 in n=51 infants <28 weeks' gestation). However, this was a post hoc analysis with relatively few patients and, therefore, did not influence our treatment recommendation.
Intraventricular hemorrhage (all grades), but not severe IVH, was statistically significantly decreased in the RFM visible group (low certainty). However, there is a lack of certainty whether the difference in IVH between groups in 2 RCTs (n=393 patients) was attributable to the RFM or a chance finding as IVH (all grades) was one of many secondary outcomes. The composite outcome of IVH (all grades) and periventricular leukomalacia (PVL) was not considered for this recommendation as it was a post-hoc secondary outcome.
No specific device cost or training cost were reported in these trials. However, the cost of purchasing and implementing new devices is significant. In addition, there are several human factor issues that should be addressed if RFM use were to become more widespread.
The lack of clinical benefit, except the possible benefit in reducing intraventricular hemorrhage (all grades), and the lack of cost-effectiveness data, contributed to the recommendation statement.
Knowledge Gaps
Research priorities should include human factor assessment, methods exploring opportunities to reduce inequity, and cost-benefit analysis. Standardized operational definitions for outcomes in future studies would permit meta-analysis of results such as mask leak.
Potential research questions are listed below:
Does the use of a RFM vs no RFM during neonatal resuscitation in the delivery room result in a difference in the percentage of time spent delivering a target tidal volume? [What is the definition of clinically significant mask leak (in terms of % leak and % of time spent with that degree of leak)?]
Does the use of a RFM vs no RFM during neonatal resuscitation in the delivery room result in a faster time to a heart rate > 60 (and > 100bpm)?
What is the optimal manner in which RFM data and alarms should be displayed to achieve its most accurate and timely acquisition, interpretation and translation to actionable information?
What are the training requirements to achieve and maintain competency in the acquisition and accurate interpretation of data derived from RFM during neonatal resuscitation?
What is the cost effectiveness for the use of RFM (vs no RFM) during neonatal resuscitation?
Attachments: NLS 806 RFM Et D
References
- Dupont WD and Plummer WD: PS power and sample size program available for free on the Internet. Controlled Clin Trials,1997;18:274
- Perlman JM, Wyllie J, Kattwinkel J et.al. Part 7: Neonatal Resuscitation. 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation.2015;132:S204-241.
- Schmölzer GM, Morley CJ, Wong C, et al. Respiratory function monitor guidance of mask ventilation in the delivery room: a feasibility study. J Pediatr. 2012;160(3):377-381.e2.
- Sterne JAC, Savovic J, Page MJ et.al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:I4898.
- Strand ML, Simon WM, Wyllie J, Wyckoff MH, Weiner G. Consensus outcome rating for international neonatal resuscitation guidelines. Arch Dis Child Fetal Neonatal Ed.2020;105:328-330.
- van Zanten HA, Kuypers KLAM, van Zwet EW, van Vonderen JJ, Kamlin COF, Springer L, Lista G, Cavigioli F, Vento M, Núñez-Ramiro A, Oberthuer A, Kribs A, Kuester H, Horn S, Weinberg DD, Foglia EE, Morley CJ, Davis PG, Te Pas AB. A multi-centre randomised controlled trial of respiratory function monitoring during stabilisation of very preterm infants at birth. Resuscitation. 2021 Oct;167:317-325.
- Zeballos Sarrato G, Sánchez Luna M, Pérez Pérez A, et al. New Strategies of Pulmonary Protection of Preterm Infants in the Delivery Room with the Respiratory Function Monitoring. Amer J Perinatol. 2019;1–9.